When.com Web Search

  1. Ads

    related to: alk positive lung cancer

Search results

  1. Results From The WOW.Com Content Network
  2. ALK positive lung cancer - Wikipedia

    en.wikipedia.org/wiki/ALK_positive_lung_cancer

    ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein, most frequently, the echinoderm microtubule-associated protein-like 4 gene is fused to the anaplastic lymphoma kinase (ALK) gene.

  3. Pfizer drug extends life for patients with rare lung cancer ...

    www.aol.com/news/pfizer-drug-extends-life...

    The drug treats a type of non-small cell lung cancer with a genetic mutation called ALK. Non-small cell lung cancers account for about 85% of lung cancer diagnoses, and ALK-positive cancers ...

  4. Anaplastic lymphoma kinase - Wikipedia

    en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase

    Xalkori , produced by Pfizer, was approved by the FDA for treatment of late stage lung cancer on August 26, 2011. [76] Early results of an initial Phase I trial with 82 patients with ALK induced lung cancer showed an overall response rate of 57%, a disease control rate at 8 weeks of 87% and progression free survival at 6 months of 72%.

  5. Ensartinib - Wikipedia

    en.wikipedia.org/wiki/Ensartinib

    Efficacy was evaluated in eXALT3 (NCT02767804), an open-label, randomized, active-controlled, multicenter trial in 290 participants with locally advanced or metastatic ALK-positive non-small cell lung cancer who had not previously received an ALK-targeted therapy. [2] Participants were randomized 1:1 to receive ensartinib or crizotinib. [2]

  6. Pfizer's Lorlatinib Scores European Approval In ALK-Positive ...

    www.aol.com/news/pfizers-lorlatinib-scores...

    The European Commission has approved Pfizer Inc's (NYSE: PFE) Lorviqua (lorlatinib) for a form of advanced non-small-cell lung cancer (NSCLC). Lorlatinib is available in the U.S. under the brand ...

  7. Crizotinib - Wikipedia

    en.wikipedia.org/wiki/Crizotinib

    Approval required a companion molecular test for the EML4-ALK fusion. In March 2016, the FDA approved crizotinib in ROS1-positive non-small cell lung cancer. [19] In October 2012, the European Medicines Agency (EMA) approved the use of crizotinib to treat non-small cell lung cancers that express the abnormal anaplastic lymphoma kinase (ALK ...

  1. Ads

    related to: alk positive lung cancer